BNP Paribas Asset Management
ACAD icon

BNP Paribas Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History

BNP Paribas Asset Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$38.2K Sell
1,509
-221
-13% -$4.86K ﹤0.01% 1854
2026
Q1 		$38.5K Buy
1,730
+309
+22% +$7.38K ﹤0.01% 1831
2025
Q4 		$38K Buy
+1,421
New +$34K ﹤0.01% 1742
2025
Q3 		– Sell
-849
Closed -$18K – 1863
2025
Q2 		$18K Buy
+849
New +$15.8K ﹤0.01% 1529

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BNP Paribas Asset Management's ACAD Position: Q2 2026 in Review

BNP Paribas Asset Management reduced its Acadia Pharmaceuticals (ACAD) stake by 13% in Q2 2026, selling an estimated $4.86K and leaving 1,509 shares worth $38.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1854.

BNP Paribas Asset Management first reported a position in ACAD in Q2 2025 and has held it in 4 quarters since. The position peaked at $38.5K in Q1 2026. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • BNP Paribas Asset Management held 1,509 shares of Acadia Pharmaceuticals worth $38.2K as of Q2 2026.
  • BNP Paribas Asset Management sold 221 Acadia Pharmaceuticals shares in Q2 2026, an estimated $4.86K.
  • Acadia Pharmaceuticals made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q2 2026, its #1854 holding.
  • BNP Paribas Asset Management first reported a position in Acadia Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • BNP Paribas Asset Management's Acadia Pharmaceuticals position peaked at $38.5K in Q1 2026.
  • 354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.